EGFR and Hepatitis: However, the incidences of treatment-related hepatitis and bleeding were higher, although not significantly, in the EGFR-TKI plus bevacizumab group than in the EGFR-TKI plus ramucirumab group (19.1% vs. 6.1%, p = 0.055; 8.5% vs. 2.1%, p = 0.156; respectively).